Report: Payers may require more clinical data on follow-on biologics

08/9/2011 | PharmaTimes (U.K.)

FDA approval might not be enough for insurers to cover generic copies of biotech drugs, according to a report from Decision Resources. "Because [monoclonal antibodies] are highly complex biologics compared with more simple proteins, FDA approval will only go part way in satisfying payers' doubts over these more elaborate agents," said Andrew Merron, biosimilars advisory service director at Decision Resources. The FDA is still working on a definition for "similar" in the context of biologic drugs and is unlikely to promulgate a one-size-fits-all rule, agency officials said.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC